New research by Humana and Boehringer Ingelheim Pharmaceuticals Inc., a global pharmaceutical company with nearly a century of experience in respiratory health, will make it easier for physicians to help Humana members adhere to their medications.
The two companies have announced the publication of a new study showing an association between non-adherence to medications for many chronic diseases and non-adherence to COPD medications. This new study was published in Volume 12, 2017, of the academic journal, International Journal of COPD.
“These findings are important, because they help guide physicians on how best to support COPD patients with historically low adherence in taking their medications so they can achieve optimal health outcomes,” said Dr. Andrew Renda, M.D. MPH, Bold Goal Director for Humana. “Rather than focus on the number and type of comorbidities with COPD, holistic adherence improvement efforts should address access, affordability, and most importantly, education on how these medications improve symptoms and quality of life while reducing the risk of exacerbations.”
COPD is a progressive respiratory disease characterized by increased breathlessness, frequent coughing, wheezing and tightness in the chest. Although there is no cure for COPD, healthcare providers often choose to prescribe daily maintenance medications to treat symptoms and reduce the risk of exacerbations, which are a sudden onset of COPD symptoms that can lead to hospitalizations or even death.